PTO/SB/53 (04-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)

In re Application of	
Application Number: 09/920,215	Filed: 8-1-01
Art Unit	Examiner

Paper No._____

Assistant Commissioner for Patents
Washington, DC 20231

1. ☐ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☐ (A) referred to in:

United States Patent Application Publication No. 2002/0099092, page _____, line_____,

United States Patent Number_____, column _____, line _____, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. _____, page _____, line_ ____.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or 1.14(e)(2)(i), i.e., Application No._____, paper No. _____, page _____, line _____.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

Signature

6-23-03
Date

Ivan Chau
Typed or printed name

FOR PTO USE ONLY

Approved by: _____
(initials)

Unit: _____

US 20020099092A1

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2002/0099092 A1

Blakemore et al. (43) Pub. Date: Jul. 25, 2002

(54) ALKYL AMINO ACID DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS

(76) Inventors: **David Clive Blakemore**, Cambridgeshire (GB); **Justin Stephen Bryans**, Balsham (GB); **Sophie Caroline Williams**, Cambridge (GB)

Correspondence Address:
Charles W. Ashbrook
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105 (US)

(21) Appl. No.: **09/920,215**

(22) Filed: **Aug. 1, 2001**

(30) **Foreign Application Priority Data**

Aug. 1, 2000 (GB) 0018828.4

Publication Classification

(51) **Int. Cl.**[7] **A61K 31/198**; A61K 31/195; A61K 31/22

(52) **U.S. Cl.** **514/551**; 514/561; 560/38; 560/155; 562/443

(57) ABSTRACT

GABA-related pro-drugs of the formula (III) are provided that when administered to humans or other mammals provide an increased duration of active compound in the plasma compared to compounds of corresponding structure in which labile groups are not present. The compounds are of the formula (III)

(III)



In the above formula:

P represents hydrogen or methyl;

Q represents a labile amine- or amide-forming organic group that becomes removed in the human or animal body;

R^1 represents straight or branched C_2-C_6 alkyl, C_3-C_6 cycloalkyl or phenyl;

R^2 represents hydrogen or methyl; and

R^3 represents hydrogen, methyl or carboxyl; and

R^4 represents hydrogen or a labile ester-forming group selected from substituted and unsubstituted C_1-C_6 alkyl, benzyl and phenyl groups that become removed in the human or animal body. In the above formula when R^1 is phenyl, R^2, R^3 and R^4 are not simultaneously hydrogen. Pharmaceutically acceptable salts of any salt-forming compound within the above class are also included. The compounds may be used to treat a range of neurological conditions, e.g. epilepsy and pain.